Ultomiris vs. Soliris

Ultomiris (ravulizumab-cwvz) and Soliris (eculizumab) are monoclonal antibodies used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).

Soliris is also used to treat atypical hemolytic uremic syndrome (aHUS).

Side effects of Ultomiris and Soliris that are similar include headache, diarrhea, and nausea.

Side effects of Ultomiris that are different from Soliris include upper respiratory infection, abdominal pain, fever, pain in extremities, joint pain, and dizziness.

Side effects of Soliris that are different from Ultomiris include tiredness, vomiting, muscle pain, back pain, and cold symptoms such as stuffy nose, sneezing, or sore throat.

Both Ultomiris and Soliris may interact with other drugs.

Common side effects of Ultomiris include:

• upper respiratory infection,
• headache,
• diarrhea,
• nausea,
• abdominal pain,
• fever,
• pain in extremities,
• joint pain, and
• dizziness

Common side effects of Soliris include:

• headache,
• tiredness,
• nausea,
• vomiting,
• diarrhea,
• muscle pain,
• back pain, or
• cold symptoms such as stuffy nose, sneezing, or sore throat.

Tell your doctor if you have serious side effects of Soliris including:

• signs of infection (such as fever, persistent cough or sore throat, painful or frequent urination),
• muscle cramps,
• swelling hands/ankles/feet,
• fast heartbeat, or
• changes in the amount of urine.

Ultomiris (ravulizumab-cwvz) is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Soliris (eculizumab) is a monoclonal antibody that binds to proteins in the blood that can destroy red blood cells in people with a genetic condition that affects the natural defenses of red blood cells used to prevent the breakdown of red blood cells in people with paroxysmal nocturnal hemoglobinemia (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS).

Ultomiris may interact with other drugs. Tell your doctor all medications and supplements you use.

Other drugs may interact with Soliris. Tell your doctor all prescription and over-the-counter medications and supplements you use. During pregnancy, Soliris should be used only when prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

The recommended dosing regimen of Ultomiris for adult patients with PNH consists of a loading dose followed by maintenance dosing, administered by intravenous infusion. Doses are administered based on the patient's body weight.

The Soliris therapy dosing regimen to treat PNH in adults consists of: 600 mg weekly for the first 4 weeks, followed by 900 mg for the fifth dose 1 week later, then 900 mg every 2 weeks thereafter. The dosing regimen to treat aHUS in adults consists of: 900 mg weekly for the first 4 weeks, followed by 1200 mg for the fifth dose 1 week later, then 1200 mg every 2 weeks thereafter.